Activation of RAS family members confers resistance to ROS1 targeting drugs-Reference-Cited by-同舟云学术

Activation of RAS family members confers resistance to ROS1 targeting drugs

Published:2014-12-31 Issue:7 Volume:6 Page:5182-5194
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Cargnelutti Marilisa¹,Corso Simona¹²,Pergolizzi Margherita¹,Mévellec Laurence³,Aisner Dara L.⁴,Dziadziuszko Rafal⁵,Varella-Garcia Marileila⁴⁶,Comoglio Paolo M.¹²,Doebele Robert C.⁶,Vialard Jorge⁷,Giordano Silvia¹²

Affiliation:

1. Candiolo Cancer Institute - FPO, IRCCS, Torino, Italy

2. Department of Oncology, University of Torino, Italy

3. Janssen Research & Development, Janssen-Cilag, Val-de-Reuil, France

4. Department of Pathology, University of Colorado School of Medicine, Aurora, CO, USA

5. Medical University of Gdansk, Poland

6. Department of Medicine, Division of Medical Oncology University of Colorado School of Medicine, Aurora, CO, USA

7. Janssen Research & Development, a division of Janssen Pharmaceutica NV, Beerse, Belgium

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 73 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prevalence of KRAS amplification in patients with metastatic cancer: Real-world next-generation sequencing analysis;Pathology - Research and Practice;2024-09

2. Differential network analysis of ROS1 inhibitors reveals lorlatinib polypharmacology through co-targeting PYK2;Cell Chemical Biology;2023-10

3. Therapeutical Options in ROS1—Rearranged Advanced Non Small Cell Lung Cancer;International Journal of Molecular Sciences;2023-07-15

4. Evolution of acquired resistance in a ROS1+ KRAS G12C+ NSCLC through the MAPK pathway;npj Precision Oncology;2023-01-23

5. Non-Small Cell Lung Cancer Targeted Therapy: Drugs and Mechanisms of Drug Resistance;International Journal of Molecular Sciences;2022-12-01